RxDoctor Payments Data

Jarod Williams, NP

Primary Care · Visalia, CANPI 1588156236

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 767 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,114in general payments, 2019–2025

Across 767 payments — averaging $15.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$770
  • Amgen$602
  • Boehringer Ingelheim$584
  • Biohaven Pharmaceutical Holding Company Ltd.$442
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$12,092100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie87$1,621
Novo Nordisk171$1,419
Lilly USA, LLC63$770
Amgen33$602
Boehringer Ingelheim33$584
Biohaven Pharmaceutical Holding Company Ltd.36$442
Takeda Pharmaceuticals U.S.A., Inc.30$435
Mylan Specialty L.p.19$419
Pfizer28$393
AstraZeneca(2 entities)21$383
Corcept Therapeutics12$358
Bayer13$338
Otsuka America Pharmaceutical, Inc.14$286
Merck16$284
Biohaven Pharmaceuticals, Inc.19$280
Abiomed5$174
Xeris Pharmaceuticals, Inc.10$172
Lexicon Pharmaceuticals, Inc.4$167
Axsome Therapeutics, Inc.6$149
Amarin Pharma, Inc.13$144
Antares Pharma, Inc.6$140
Astellas Pharma US Inc7$136
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$127
GSK7$123
Therapeuticsmd, Inc.7$123
Ironwood Pharmaceuticals, Inc7$110
Agile Therapeutics, Inc.6$106
Phathom Pharmaceuticals, Inc.5$102
Lundbeck LLC4$102
Qiagen, LLC4$100
Organon6$92
Johnson & Johnson5$92
Idorsia Pharmaceuticals US Inc5$87
Viiv Healthcare Company1$85
Shield Therapeutics Inc4$84
Verity Pharmaceuticals Inc.4$76
Mayne Pharma Commercial LLC5$75
Abbott3$74
Daiichi Sankyo Inc.3$70
Dexcom, Inc.3$68
Vanda Pharmaceuticals Inc.3$56
Halozyme Inc2$53
Myovant Sciences Inc.3$52
Medtronic2$51
Hologic Sales And Service, LLC2$49
Viatris Specialty LLC2$43
Arbor Pharmaceuticals, Inc.2$36
Evofem Biosciences, Inc.2$35
Nalu Medical, Inc.1$32
Recordati_rare_diseases_inc.1$31
Novartis2$29
Tempus AI, Inc1$27
Nestle Healthcare Nutrition Inc.1$25
Coopersurgical, Inc.1$24
Optinose US, Inc.1$19
Genentech USA, Inc.1$19
Mimedx Group, Inc.1$18
Cranial Technologies, Inc1$18
Seqirus USA Inc1$17
Neurocrine Biosciences, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,114 in reported general payments places this provider in the 95th percentile of 706 primary care providers in California.

See all primary care providers in California

Medicare billing

Part B allowed, 2024
$226,989
Medicare patients
346
Services billed
4,096

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$34,140
EliquisApixaban43$25,570
JardianceEmpagliflozin14$18,278
LinzessLinaclotide13$13,066
FarxigaDapagliflozin Propanediol19$12,226
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,922
Valsartan46$1,544
Estradiol13$1,478
Fluconazole17$1,204
Duloxetine Hcl21$894
Atorvastatin Calcium66$889
Alprazolam107$866
Omeprazole50$819
Rosuvastatin Calcium57$741
Testosterone Cypionate15$697

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,419$34,14031 claims
PfizerEliquis$393$25,57043 claims
Boehringer IngelheimJardiance$584$18,27814 claims
AbbVieLinzess$1,621$13,06613 claims
AstraZenecaFarxiga$383$12,22619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 706 primary care providers in California.

Other primary care in Visalia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →